Goral S, Felgar R, Shappell S
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2372, USA.
Am J Kidney Dis. 1997 Aug;30(2):301-7. doi: 10.1016/s0272-6386(97)90071-8.
As a complication of immunosuppressive therapy, solid organ and bone marrow transplant recipients have an increased risk of developing post transplant lymphoproliferative disorder (PTLD). Epstein-Barr virus (EBV) infection and the degree of immunosuppression have been identified as risk factors for the development of this complication. The clinical presentation includes a spectrum of disorders ranging from a benign infectious mononucleosis-like syndrome with fever and cervical adenopathy to multiorgan failure leading to death. Although, T-cell lesions have been described, PTLD is usually associated with a polyclonal or monoclonal B-cell proliferation. In this report, we present a renal transplant recipient with a perirenal mass diagnosed as PTLD.
作为免疫抑制治疗的一种并发症，实体器官和骨髓移植受者发生移植后淋巴细胞增生性疾病（PTLD）的风险增加。爱泼斯坦-巴尔病毒（EBV）感染和免疫抑制程度已被确定为发生这种并发症的风险因素。临床表现包括一系列疾病，从伴有发热和颈部淋巴结病的良性传染性单核细胞增多症样综合征到导致死亡的多器官衰竭。虽然已有T细胞病变的描述，但PTLD通常与多克隆或单克隆B细胞增殖有关。在本报告中，我们介绍了一名肾移植受者，其肾周肿块被诊断为PTLD。
